Analysts see hot prospects in Amicus pipeline

Newly public Amicus Therapeutics is attracting some positive attention from the analysts, who have been impressed by the company's swift advances on the clinical development front. JP Morgan analyst Geoffrey Meacham notes Amicus' looming Phase III trial for Fabry disease and a scheduled release of mid-stage data on a Gaucher disease candidate in the second half of next year. A third candidate is in Phase I for Pompe disease. Amicus specializes in lysosomal storage diseases, or LSD's. Investors haven't been particularly enthusiastic about the company, though. Amicus went public May 31 at $16 a share and has since seen its stock price slide 20 percent.

- read the report from The Boston Globe

ALSO: A closer look at the IPOs of Amicus Therapeutics, Jazz Pharmaceuticals and Sirtris Pharmaceuticals. Report

Related Articles:
Amicus Therapeutics outlines $86M IPO. Report
Amicus gins $55M in third round, outlines Phase II. Report
Genzyme sees big returns from small drug market. Report

Suggested Articles

The clamor for more transparency from the leading pandemic vaccine contenders has been getting louder.

The role gives one of the driving forces behind Bristol Myers Squibb’s $74 billion takeover of Celgene the chance to help build biotechs.

The appointment gives Sino-American biotech Brii the experience of a man who helped Gilead launch eight drugs in China in quick succession.